Nanocarriers can often achieve superior therapeutic outcomes for drug delivery when compared with standard drug formulations. However, concerns over their adverse effects are growing due to the correlation between exposure to nanosized particles and cardiovascular diseases. Here we examine the impact of intravenously injected drug-free nanocarriers on the cardiovasculature at both systemic and organ levels. We combine in vivo and in vitro methods to enable monitoring of hemodynamic parameters in conscious rats, assessments of the function of the vessels after sub-chronic systemic exposure to nanocarriers and evaluation of the direct effect of nanocarriers on vascular tone.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Autonomic Neuroscience: Basic and Clinical
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Received: May 15, 2013
© 2013 Published by Elsevier Inc.